HAEMONETICS CORP

For the period ended Mar 30, 2024. Filed Jun 7, 2024.

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Mar 30, 2024 · Filed Jun 7, 2024

HAE$119.93-3.4%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

Filed by the Registrant x	Filed by a Party other than the Registrant ☐

Check the appropriate box:
☐	Preliminary Proxy Statement
☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
x	Definitive Proxy Statement
☐	Definitive Additional Materials
☐	Soliciting Material under §240.14a-12

HAEMONETICS CORPORATION

(Name of Registrant as Specified in Its Charter)

Payment of Filing Fee (Check the appropriate box):
x	No fee required.
☐	Fee paid previously with preliminary materials.
☐	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

OUR PURPOSEwe make it possibleyou make it matterWe challenge ourselves every day to drive greater possibilities and meaningfully advance healthcare.

Haemonetics provides a suite of innovative medical technology solutions that improve the quality, effectiveness and efficiency of care. We challenge ourselves to think big and make new possibilities a reality, so that our customers can make it matter for patients, every single day.WHAT WE DOFor commercial plasma, we offer innovative technologies that enable high plasma yield collections, improve productivity and quality in our customers’ centers and enhance the overall donor experience.For hospitals, we provide information and solutions that enable healthcare professionals to improve patient care and economic outcomes in critical settings.For blood centers, we advance products and services to help ensure blood safety, improve operational efficiency and collect the blood components in the greatest demand.

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS

Thursday, July 25, 2024

8:00 A.M. Eastern Time

125 Summer Street, Boston, Massachusetts 02110

To Our Shareholders:

The 2024 Annual Meeting of Shareholders of Haemonetics Corporation, a Massachusetts corporation (the "Company"), will be held on Thursday, July 25, 2024 at 8:00 A.M., Eastern Time, at the offices of the Company, 125 Summer Street, Boston, Massachusetts 02110, for the following purposes:

1 To elect the nine director nominees named in the proxy statement to one-year terms expiring in 2025;

2 To approve, on an advisory basis, the compensation of our named executive officers;

3 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 29, 2025; and

4 To transact such other business as may properly come before the meeting.

The foregoing items of business are more fully described in the proxy statement accompanying this Notice of Annual Meeting of Shareholders.

We are pleased to continue utilizing the Securities and Exchange Commission rules that allow companies to furnish proxy materials to their shareholders on the Internet. We believe these rules allow us to provide you with the information you need while lowering the costs of delivery and reducing the environmental impact of the meeting. On or about June 10, 2024, we will mail to our shareholders of record as of May 22, 2024, the record date for the meeting, a Shareholder Meeting Notice and Important Notice Regarding the Availability of Proxy Materials containing instructions on how to access our proxy statement and our 2024 Annual Report to Shareholders (unless the shareholder previously requested electronic or paper delivery on an ongoing basis).

Your vote is important. Whether or not you plan to attend the meeting, we encourage you to vote your shares. Accordingly, we request that as soon as possible you vote via the Internet or, if you have received printed proxy materials, you vote via the Internet, by telephone or by mailing your completed proxy card or voter instruction form.

By Order of the Board of Directors

Michelle L. Basil

Corporate Secretary

Boston, Massachusetts

June 7, 2024

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 25, 2024: This proxy statement and the Company’s 2024 Annual Report to Shareholders are available at www.envisionreports.com/HAE.

HAEMONETICS CORPORATION | 2024 Proxy Statement 1

TABLE OF CONTENTS

Notice of Annual Meeting of Shareholders	1
Proxy Statement Summary	3
Item 1—Election of Directors	9
Haemonetics Board of Directors	9
Board’s Role and Responsibilities	13
Board Leadership Structure	14
Board Policies and Processes	16
Directors’ Compensation	17
Item 2—Advisory Vote on Executive Compensation	19
Executive Officers	20
Compensation Discussion and Analysis	22
Compensation Committee Report	37
Executive Compensation Tables	38
CEO Pay Ratio	44
Pay Versus Performance	45
Timing of Equity Awards	48
Hedging Policy	48
Item 3—Ratification of Independent Registered Public Accounting Firm	49
Audit Fees and Services	50
Audit Committee Report	50
Share Ownership Information	52
Equity Compensation Plans	52
Security Ownership of Certain Beneficial Owners, Directors and Management	53
Delinquent Section 16(a) Reports	54
General Information About the Meeting and Voting	55
Additional Information	58
Solicitation of Proxies	58
Shareholder Proposals for Next Year's Annual Meeting	58
Other Matters	58
Incorporation by Reference	58
Delivery of Documents to Shareholders Sharing an Address	59
Appendix A—Non-GAAP Financial Reconciliations	60

2 HAEMONETICS CORPORATION | 2024 Proxy Statement

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.